Payment overview · 2025
General Payments
$183.98
10 reported records · 6 companies
Healthcare provider profile · identity verified
John Franklin Simmons, MD
Allopathic & Osteopathic Physicians|Family Medicine · GENEVA, AL · NPI 1942452123
Verified facts
What the public records show
CMS Open Payments records show John Franklin Simmons, MD received $183.98 in general payments during 2025 across 10 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 41.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $75.96 | 41.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.89 | 15.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.99 | 14.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 10.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.02 | 9.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $16.27 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $165.13 | 9 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $75.96 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 289 | 96 |
| Montelukast Sodium | Montelukast Sodium | 275 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 95 |
| Omeprazole | Omeprazole | 267 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 66 |
| Meloxicam | Meloxicam | 234 | 91 |
| Furosemide | Furosemide | 219 | 74 |
| Alprazolam | Alprazolam | 198 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 60 |
| Losartan Potassium | Losartan Potassium | 172 | 48 |
| Trazodone Hcl | Trazodone Hcl | 171 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 49 |
| Topiramate | Topiramate | 147 | 54 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 49 |
| Potassium Chloride | Potassium Chloride | 142 | 42 |
| Pregabalin | Pregabalin | 142 | 60 |
| Tramadol Hcl | Tramadol Hcl | 142 | 35 |
| Oxcarbazepine | Oxcarbazepine | 132 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 54 |
| Metformin Hcl | Metformin Hcl | 126 | 38 |
| Famotidine | Famotidine | 114 | 41 |
| Simvastatin | Simvastatin | 111 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 34 |
| Clonazepam | Clonazepam | 99 | 20 |
| Carvedilol | Carvedilol | 98 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 34 |
| Ozempic | Semaglutide | 96 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 71 |
| Gabapentin | Gabapentin | 91 | 30 |
| Alendronate Sodium | Alendronate Sodium | 90 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 26 |
| Sertraline Hcl | Sertraline Hcl | 86 | 25 |
| Donepezil Hcl | Donepezil Hcl | 85 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 21 |
| Spironolactone | Spironolactone | 85 | 21 |
| Bumetanide | Bumetanide | 80 | 18 |
| Bupropion Xl | Bupropion Hcl | 80 | 32 |
| Prednisone | Prednisone | 71 | 55 |
| Mirtazapine | Mirtazapine | 70 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 54 |
| Memantine Hcl | Memantine Hcl | 67 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 19 |
| Levofloxacin | Levofloxacin | 57 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 13 |
| Mounjaro | Tirzepatide | 52 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 12 |
| Celecoxib | Celecoxib | 51 | 24 |
| Eliquis | Apixaban | 51 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 15 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 14 |
| Terazosin Hcl | Terazosin Hcl | 42 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 24 |
| Fluconazole | Fluconazole | 41 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 12 |
| Tolterodine Tartrate | Tolterodine Tartrate | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 36 |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 19 |
| Glipizide | Glipizide | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 20 |
| Lactulose | Lactulose | 36 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 13 |
| Digoxin | Digoxin | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 24 |
| Ondansetron Odt | Ondansetron | 32 | 21 |
| Allopurinol | Allopurinol | 31 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Nystatin | Nystatin | 28 | 18 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 24 | 23 |
| Cilostazol | Cilostazol | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 13 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 14 | 13 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.98 · 10 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, GEMTESA, JARDIANCE, QUTENZA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error